Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Disorders of Platelet Number or Function Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
A Single Point Mutation Gln716His on the α2 Integrin: The New Platelet Alloantigen CasaClinically Relevant Abstract

Gerald Bertrand1*, Vincent Jallu1*, Dominique Kervran2*, Corinne Martageix1* and Cecile Kaplan-Gouet, MD3

1Platelet Immunology, GIP-INTS, 75015 Paris, France
2Centre Hospitalier Regional, Orleans, France
3INTS, Paris, France

Thromboembolic Events among Adult Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom General Practice Research DatabaseClinically Relevant Abstract

Ameet Sarpatwari, MPhil1*, Dimitri Bennett, MD, MPH2*, John W Logie, PhD3*, Amit Shukla, BSc2*, Kathleen J Beach, MD, MPH4*, Adrian Newland, MD, FRCP5, Simon Sanderson, MD1* and Drew Provan, MD6*

1Department of Public Health and Primary Care, University of Cambridge, London, England
2WWEpidemiology Department, GlaxoSmithKline, Philadelphia, PA
3WWEpidemiology Department, GlaxoSmithKline, Greenford, England
4WWEpidemiology Department, GlaxoSmithKline, Research Triangle Park, NC
5Department of Haematology, Barts and The London School of Medicine and Dentistry, London
6Department of Haematology, Barts and The London School of Medicine and Dentistry, London, England

Purification of Anti-HPA-1a Directly from Plasma Using Immobilised Recombinant HPA-1a Enables Determination of Antibody Affinity by Surface Plasmon Resonance Technology in Neonatal Alloimmune Thrombocytopenia

Hagop Bessos, BSc, MSc, PhD, FRCPath1*, Pamela Brown, BSc, PhD2*, Gholamreza Anani Sarab, MSc3*, Shirley Gibson, MIBMS4*, Michael Moss, BSc, PhD5*, Robert N Barker, BSc, PhD3* and Stanislaw J Urbaniak, MBChB, PhD, FRCP, FRCPath6

1Research and Development, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom
2Human Reproductive Sciences Unit, Medical Research Council, Edinburgh, United Kingdom
3Department of Medicine & Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
4Processing and Testing, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom
5Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
6Department of Medicine and Therapeutics, Academic Transfusion Medicine Unit, Aberdeen, United Kingdom

Dosing Patterns and Outcomes in African American, Asian, and Hispanic Patients with Heparin-Induced Thrombocytopenia Treated with Argatroban

Marcie J Hursting, PhD1* and Ik-Kyung Jang, MD, PhD2*

1Clinical Science Consulting, Austin, TX
2Cardiology Division, Massachusetts General Hospital, Boston, MA

Profiles of Th1、Th2、Th17 and Treg Cells in Patients with Chronic Idiopathic Thrombocytopenic Purpura

Rong-Fu Zhou, Jian Ou-yang*, Da-Yu Chang*, Jing-Yan Xu*, Bing Chen*, Yong-Gong Yang*, Qi-Guo Zhang* and Xiao-Yan Shao*

Hematology, Nanjing Drum Tower Hospital of Nanjing University, Nanjing, China

Excluding HIT Diagnosis by a Particle Gel Immunoassay

Katharina Schallmoser1*, Camilla Drexler1*, Eva Rohde1*, Dirk Strunk2, Andrea Groselj-Strele3*, Gerhard Lanzer1*, Hartmut Kroll4* and Simon Panzer5*

1University Clinic of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria
2Department of Hematology and Stem Cell Transplantation, University Clinic of Internal Medicine, Medical University of Graz, Graz, Austria
3Medical Research Center, Medical University of Graz, Graz, Austria
4Institute for Transfusion Medicine Dessau, Red Cross Blood Transfusion Service NSTOB, Dessau, Germany
5Clinical Department of Blood Group Serology, Medical University of Vienna, Vienna, Austria

Clinical Characterization of a Novel Oral Thrombopoietin Mimetic LGD-4665 in Healthy Volunteers Demonstrate Safe and Sustained Increases in Platelet Counts with Flexible Dosing Choices for Phase II TrialsClinically Relevant Abstract

Zofia E. Dziewanowska, MD, PhD1, Ram P. Kapil, PhD1*, J. K. Zhang, PhD1*, Jolene K. Berg, MD2*, Victor J. Stevens, PhD1*, Richard M. Matsumoto, PhD1*, Lisa Greenberg1* and Maryanna Y. Morris1*

1Clinical Research, Ligand Pharmaceuticals, San Diego, CA
2CEDRA Clinical Research, San Antonio, TX

Regulation of An Acquired Inhibitor to the GPVI Platelet Collagen Receptor in a Patient with An Autoimmune Syndrome and Kidney Disease

Paquita Nurden1*, Narendra Tandon2*, Hisao Takizawa2*, Xiaoqi Gong2*, Alice Conception2*, Delphine Morel3*, Pierre Merville3*, Sebastien Loya4*, Martine Jandrot-Perrus4* and Alan T. Nurden1

1Centre de Référence des Pathologies Plaquettaires/Plateforme Technologique et d'Innovation Biomédicale, Hôpital Xavier Arnozan, Pessac, France
2Otsuka Maryland Medicinal Labs Inc, Rockville, MD
3Service de Transplantation Rénale, CHU Bordeaux, Bordeaux, France
4Inserm U698, CHU Xavier Bichat, Paris, France

Cell-Based Immunotherapy with Different Subsets of Tolerogenic Dendritic Cell in Idiopathic Thrombocytopenic Purpura

Xiao-Lin Zhang, PhD*, Jun Peng, MD*, Shu-Qian Xu*, Xin-Guang Liu*, Yuan Yu, MD*, Ping Qin, MD*, Yan Shi, PhD*, Lin Wang, PhD* and Ming Hou, MD, PhD*

Department of Hematology, Qilu Hospital, Shandong University, Jinan, China

The Feature of TCR Vγ And TCR Vδ Repertoire Distribution and Clonality in Patients with Immune Thrombocytopeinc Purpura

Xueli Zhang1*, Shaohua Chen2*, Lijian Yang2*, Kanger Zhu, MD1 and Yangqiu Li2

1Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
2Institute of Hematology, Medical College, Jinan University, Guangzhou, China

Alteration of Circulating Regulatory T Cells in Japanese Adult Patients with Immune Thrombocytopenic Purpura after Eradication of Helicobacter PyloriClinically Relevant Abstract

Koji Miyazaki, MD, PhD*, Mikio Danbara*, Manabu Ohsaka*, Yuhko Suzuki*, Ryouichi Horie* and Masaaki Higashihara*

Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan

Changing Trends in ITP Management from 1995 to 2007: An Interim Report from the UK Paediatric ITP RegistryClinically Relevant Abstract

John D. Grainger, MD, BMBch, MRCP, FRCPATH1, Joanne L Rees1*, Marie Reeves1* and Paula HB Bolton-Maggs, BMBch, DM, FRCP, FRCPath2

1Royal Manchester Children's Hosp., Manchester, United Kingdom
2Dept. of Clinical Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II StudyClinically Relevant Abstract

Howard A. Liebman, MA, MD1, Mansoor N. Saleh, MD2*, Rashid Abassi, MD3*, Thomas M. Cosgriff, MD4, Nick Teoh, PhD5*, Matthew J Leoni, MD5*, William Wegener, MD, PhD5 and David M Goldenberg, ScD, MD5*

1Jane Anne Nohl Division of Hematology, University of Southern California-Keck School of Medicine, Los Angeles, CA
2Georgia Cancer Specialists, Atlanta, GA
3Hematology Oncology Specialists, Denville, NJ
4Hematology Oncology Specialists, Metairie, LA
5Immunomedics, Inc., Morris Plains, NJ

The Efficacy of H. pylori Eradication Therapy in H. pylori-Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic ReviewClinically Relevant Abstract

Donald M. Arnold, MD1, Ashley Bernotas2*, Ishac Nazi, PhD3*, Roberto Stasi, MD4*, Masataka Kuwana, MD, PhD5*, John G. Kelton, MD, FRCPC1 and Mark A. Crowther, MD6

1McMaster University, Hamilton, ON, Canada
2Medicine, McMaster University, Hamilton, ON, Canada
3Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
4Ospedale Regina Apostolorum, Albano Laziale, Italy
5Medicine, Keio University School of Medicine, Tokyo, Japan
6St. Joseph's Hospital and McMaster University, Hamilton, Ontario, Canada

Polymorphisms in TNFA and CTLA-4 Genes and the Risk of Heparin Induced Thrombocytopenia

Dorothee Leroux1*, Claire Pouplard, PharmD, PhD1*, Benoit Guillet, MD, PhD2*, Beatrice Cosne1*, Marc Antoine May, MD3* and Yves Gruel, MD1

1Dept. Hematology-Hemostasis, University Hospital of Tours, Tours, France
2Dept. Hematology-Hemostasis, University Hospital of Rennes, Rennes, France
3Dept Anesthesiology, University hospital of Tours, Tours, France

Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP)Clinically Relevant Abstract

Howard Liebman, MD, FACP1, David Henry, MD2, Francois Lefrere, MD3*, Jean-Francois Viallard, MD4*, Alan Lichtin, MD5, James George, MD6, Miguel Sanz, MD, PhD7*, Kathy Zhang, PhD8* and Mark Rutstein, MD9*

1Jane Anne Nohl Division of Hematology, University of Southern California, Keck School of Medicine, Los Angeles, CA
2Joan Karnell Cancer Center, Philadelphia, PA
3Service d'Hematologie Adulte, Paris Cedex 15, France
4Medecine Interne - Maladies Infectieuses, Pessac, France
5The Cleveland Clinic Foundation, Cleveland, OH
6University of Oklahoma Health Sciences Center, Oklahoma City, OK
7Hospital Universitario La Fe, Valencia, Spain
8Amgen Inc., South San Francisco, CA
9Amgen Inc., Thousand Oaks, CA

Evaluation of Bone Marrow Reticulin Formation in Romiplostim-Treated Adult Patients with Chronic Immune Thrombocytopenic Purpura (ITP)Clinically Relevant Abstract

David J Kuter, MD, DPhil1, Ghulam Mufti, MD2*, Barbara Bain, MD3*, Robert Hasserjian, MD1 and Mark Rutstein, MD4*

1Massachusetts General Hospital, Boston, MA
2King's College Hospital, London, United Kingdom
3St. Mary's Hospital, London, United Kingdom
4Amgen Inc., Thousand Oaks, CA

Apoptosis in Platelets from Pediatric Patients with Acute Immune Thrombocytopenic Purpura (ITP) Is Ameliorated by IV IgClinically Relevant Abstract

Oliver Speer, PhD1*, Markus Schmugge, MD1, Imane Azzouzi1*, Margaret L. Rand2 and Sabine Kroiss, MD1*

1Haematology, University Children's Hospital Zurich, Zurich, Switzerland
2Haematology, The Hospital for Sick Children, Toronto, ON, Canada

PTPN22 Mutation Is Present in An Increased Proportion of ITP Patients

Karl D'Silva, MD1*, Mathew Zamora, BS2*, John Gerlach, PhD3* and Kenneth A. Schwartz, MD4

1Medicine, Michgian State University, East Lansing, MI
2Biomedical Laboratory Diagnostics, Michgian State University, East Lansing, MI
3Biomedical Laboratory Diagnostics, Michigan State Univeristy, East Lansing, MI
4Dept. of Medicine, Michigan State University, East Lansing, MI

Drug Dependent Immune Destruction of Human Platelets in the NOD/SCID Mouse

Daniel W. Bougie, PhD1, Brian Boylan1*, Dhirendra Nayak1*, Peter J. Newman, PhD1 and Richard H. Aster, MD2

1BloodCenter of Wisconsin, Milwaukee, WI
2Blood Research Institute, BloodCenter Wisconsin, Milwaukee, WI

Rare SOX13 Sequence Variations in Pediatric Idiopathic Thrombocytopenic Purpura Patients

Johannes R Rischewski, MD1*, Johanna Wyss1*, Sylvie Stocker1*, Martin Hergersberg, PhD2*, Andreas R Huber, MD2 and Thomas Kühne, MD1*

1Pediatric Oncology/ Hematology, University Children's Hospital Basel, Basel, Switzerland
2Center for Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland

Comparison of Positive Two-Step PF4-Polyvinylsulfonate Antigen Assay Results with Thrombotic Risk and Clinical Outcome among 182 Patients with Heparin-Induced Thrombocytopenia (HIT)Clinically Relevant Abstract

James N. Frame, M.D.1, Elaine A. Davis, Ed.D., R.N.2* and Ying Wang, Ph.D.2*

1Hematology/Oncology, Charleston Area Medical Center, Charleston, WV
2CAMC Health Education and Research Institute, Charleston, WV

Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic PurpuraClinically Relevant Abstract

Michael Tarantino, MD1*, Usha Sunkara, MD2*, James George, MD3, Louis M. Aledort, MD4, Matthew Guo, PhD5*, Dietmar Berger, MD, PhD6 and Terry Gernsheimer, MD7

1Comprehensive Bleeding Disorders Center, Peoria, IL
2Alta Bates Comprehensive Cancer Center, Berkley, CA
3University of Oklahoma Health Sciences Center, Oklahoma City, OK
4Mount Sinai Hospital, New York, NY
5Amgen Inc., Thousand Oaks, CA
6Amgen, Inc., Thousand Oaks, CA
7Puget Sound Blood Center, Seattle, WA

Correlation of PF4 ELISA Results and Clinical Likelihood of HIT: Can We Improve on Specificity?Clinically Relevant Abstract

Janice McFarland, MD1, Brian R Curtis, MT, SBB, MS1*, Andrew J Lochowicz1*, Portia L Gough1*, Lisa Jahn1* and Richard H. Aster, MD2

1Platelet and Neutrophil Immunology Laboratory, BloodCenter of Wisconsin, Milwaukee, WI
2Blood Research Institute, BloodCenter Wisconsin, Milwaukee, WI

Oral Eltrombopag Treatment Reduces the Need for Concomitant Medications in Patients with Chronic Idiopathic Thrombocytopenic PurpuraClinically Relevant Abstract

Patrick F. Fogarty1, James B Bussel2, Gregory Cheng3*, Mansoor N Saleh4*, Balkis Meddeb5*, Christine Bailey6* and Andres Brainsky6*

1University of California, San Francisco, San Francisco, CA
2Weill-Cornell Medical College of Cornell University, New York, NY
3Chinese University of Hong Kong, Shatin, NT, Hong Kong
4Georgia Cancer Specialists, Atlanta, GA
5Hôpital La Rabta, Tunis, Tunisia
6GlaxoSmithKline, Collegeville, PA

Low Immunogenicity to Romiplostim in Clinical Studies with ITP SubjectsClinically Relevant Abstract

Vibha Jawa, PhD1*, Martha Hokom1*, Jenny Hu1*, Yao Zhuang, PhD1*, Dietmar Berger, MD, PhD2, Shalini Gupta, PhD1*, Steven Swanson, PhD1* and Naren Chirmule, PhD1*

1Clinical Immunology, Amgen,Inc, Thousand Oaks, CA
2Amgen, Inc., Thousand Oaks, CA

Maternal Immune Response to Fetal Platelet GPIbα Causes More Frequent Miscarriage in An Animal Model: A Potential Explanation for Low Reported Incidence of Fetal and Neonatal Immune Thrombocytopenia Mediated by Anti-GPIbα Antibodies

Conglei Li, MD1*, Siavash Piran, MSc.1*, Pingguo Chen, PhD2*, Sean Lang, BSc.1*, Jerry Ware, PhD3, Zaverio M. Ruggeri, MD3, John Freedman, MD4 and Heyu Ni, MD, PhD5*

1Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada
2Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital and Canadian Blood Services, Toronto, ON, Canada
3Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
4Departments of Laboratory Medicine and Pathobiology, and Medicine, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada
5Departments of Laboratory Medicine and Pathobiology, Medicine and Physiology, St. Michael's Hospital, University of Toronto and Canadian Blood Services, Toronto, ON, Canada

Autoantibodies in Patients with ITP Do Not Bind to Patient-Specific Epitopes on Platelet Glycoproteins

James W Smith, BSc, MT1*, Derek Coull, BSc1*, Jane C Moore, BSc, MT1*, Ishac Nazi, PhD2*, Donald M. Arnold, MD3 and John G. Kelton, MD, FRCPC3

1Medicine, McMaster University, Hamilton, ON, Canada
2Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
3McMaster University, Hamilton, ON, Canada

The Influence of Polymorphisms of Interleukin-17F Genes on the Susceptibility and Clinical Significanse of Chronic Idiopathic Thrombocytopenic Purpura

Takayuki Saitoh1*, Tetsuhiro Kasamatsu2*, Akihiko Yokohama3*, Hiroshi Handa3*, Norifumi Tsukamoto4*, Masamitsu Karasawa3*, Hatsue Ogawara2*, Yoshihisa Nojima5* and Hirokazu Murakami, MD6

1Gunma University Graduate School of Medicine, Department of Medicine and Clinical Science, Maebashi, Japan
2School of Health Sciences, Faculty of Medicine, Gunma University, Maebashi, Japan
3Gunma University Graduate School of Medicine, Department of Medicine and Clinical Science, Gunma, Japan
4Department of Medeicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan
5Gunma University Graduate School of Medicine, Department of Medeicine and Clinical Science, Maebashi, Japan
6Faculty of Medicine, Gunma University, Maebashi, Japan

Cross Reactivity of Heparin-Induced PF4 Antibodies with Heparin-Bound IL-8

Margaret Prechel, PhD1*, Abigail M Hilby, BS2* and Jeanine M. Walenga, PhD3

1Pathology, Loyola University Medical Center, Maywood, IL
2Cardiovascular Institute, Loyola University Medical Center, Maywood, IL
3Cardiovascular Institute, Loyola Univ. Medical Center, Maywood, IL

Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/µL - Data from the EXTEND StudyClinically Relevant Abstract

Gregory Cheng1*, James B Bussel2, Mansoor N Saleh3*, Balkis Meddeb4*, Maria E De Obaldia5*, Manuel Aivado5* and Nicole L Stone5*

1Chinese University of Hong Kong, Shatin, NT, Hong Kong
2Weill-Cornell Medical College of Cornell University, New York, NY
3Georgia Cancer Specialists, Atlanta, GA
4Hôpital La Rabta, Tunis, Tunisia
5GlaxoSmithKline, Collegeville, PA

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic PurpuraClinically Relevant Abstract

James B Bussel1, Bethan Psaila1*, Mansoor N Saleh2*, Sandra Vasey3*, Bhabita Mayer4*, Nicole L Stone3* and Michael Arning3*

1Weill-Cornell Medical College of Cornell University, New York, NY
2Georgia Cancer Specialists, Atlanta, GA
3GlaxoSmithKline, Collegeville, PA
4GlaxoSmithKline, Stockley Park, United Kingdom

Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic PurpuraClinically Relevant Abstract

James B Bussel1, Gregory Cheng2*, Mansoor N Saleh3*, Balkis Meddeb4*, Christine Bailey5*, Nicole L Stone5* and Manuel Aivado5*

1Weill-Cornell Medical College of Cornell University, New York, NY
2Chinese University of Hong Kong, Shatin, NT, Hong Kong
3Georgia Cancer Specialists, Atlanta, GA
4Hôpital La Rabta, Tunis, Tunisia
5GlaxoSmithKline, Collegeville, PA

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus RomiplostimClinically Relevant Abstract

Wendy Oatis, MD, JD1, Veena Shankaran, MD2*, Faisal Saghir, MD3*, Charles L. Bennett, MD, PhD, MPP2, Elizabeth Richey, BA4* and James B Bussel5

1Division of Hematology and Oncology,, Northwestern University Feinberg School of Medicine, Chicago, IL
2Hematology/Oncology, Northwestern University, Chicago, IL
3University of Illinois Chicago, Chicago
4Northwestern University, Chicago, IL
5Weill-Cornell Medical College of Cornell University, New York, NY

Comparison of Intravenous Immune Globulin and High Dose Anti-D Immune Globulin as Initial Therapy for Childhood Immune Thrombocytopenic PurpuraClinically Relevant Abstract

Ian Kane, B.S.*, Dominic Ragucci, PharmD*, Ibrahim Shatat, MD, MSCR* and Ram Kalpatthi, MD

Pediatric Hematology Oncology, Medical University of South Carolina, Charleston, SC

Health-Related Lifestyle among Adult & Pediatric Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom

Ameet Sarpatwari, MPhil1*, Shirley Watson2*, Howard Anderson2*, Drew Provan, MD3* and Adrian Newland, MD, FRCP4

1Department of Public Health and Primary Care, University of Cambridge, London, England
2ITP Support Association, Bolnhurst, United Kingdom
3Department of Haematology, Barts and The London School of Medicine and Dentistry, London, England
4Department of Haematology, Barts and The London School of Medicine and Dentistry, London, United Kingdom

*signifies non-member of ASH